Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

High Concentration Antibody - Rituximab

Challenge

Antibodies tend to aggregate at the high concentrations typically required for their therapeutic application. The key challenge of this study was to reduce the rate of aggregation in isotonic aqueous formulation of rituximab at 100 mg/ml, whilst maintaining the pH of the original product to minimise the risk of increased rate of chemical instability

ArestatT solution

Rituximab, currently a liquid product, was reformulated into an aqueous presentation at 100 mg/ml based on the ArestatT formulation tools. The control was based on a marketed formulation, working at the same concentration. Improved formulations of rituximab were achieved by application of a recently discovered variant of ArestatT technology, namely Arestat-CT. Using the principles of the Arestat-CT formulation tools, rituximab formulated at 100 mg/ml and placed on storage trial for 12 weeks at 40?C had considerably lower rates of aggregation (formation of high molecular weight species - HMWS, measured by size-exclusion chromatography) compared with that of the control

 

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024